沙美特罗替卡松联合复方丹参滴丸治疗COPD疗效分析

目的观察吸入沙美特罗替卡松、口服复方丹参滴丸治疗稳定期慢性阻塞性肺疾病（COPD）患者的临床疗效。方法将明确诊断的81例COPD患者随机分为治疗组（39例）和对照组（42例），两组病人的基础治疗相同。在此基础上，治疗组给予吸入沙美特罗替卡松（50μg／250μg），每次1吸，每日2次，口服复方丹参滴丸10粒，每日3次；对照组给予荼碱缓释片0．1g，每日2次，疗程为6个月。评估肺功能（FEV1FEV1／FVC）。结果治疗组FEV1较治疗前明显改善（P〈0．05），且明显优于对照组（P〈0．01）。结果沙关特罗替卡松联合复方丹参滴丸能提高稳定期Ⅲ-Ⅳ级COPD患者的肺功能及生活质量，改善缺氧，且安全有效P〈0．01），明显优于对照组P〈0．01）。结论沙关特罗替卡松联合复方丹参滴丸能提高稳定期Ⅲ-Ⅳ级COPD患者的肺功能及生活质量，改善缺氧，且安全有效。

Therapeutic Effects of Main Tenance Therapy with Inhaling of Salmeterol Fluticasone and Complex Danshen Droppilis in Stable Curonictive Pulmonary Disease

OBJECTIVE To observe the benefits of maintenance therapy with inhaling of salmeterol/fluticasone and complex danshen droppills（cddp）in stable chronic obstructive pulmonary disease. METHODS We screen out 81 middle or serious COPD case of stabilization period to group at random for our outpatients of 2006--2008 period. We give cortin to treat forhalf year. Weevaluate puluate pulmonary function the degree of dyspnea activity ablity（AECOPD）and bad reaction. RESULTS The analysis showed that groups with the treatment of inhaling of salmetero/flutieasone and complex danshen droppills （cddp）statistically slower descent of FEV1 than the groups of slow-release theophylline and placebo and the groups with the treatment of inhaling of salmeterol/fluticasone experienced statistically fewer numbers than the groups of slow-release theophylline and placebo. CONCLUSION Inhaling of salmetero/fluticason may be beneficial and had better compliance in long-term treatment of stable COPD.